Exploring the Mechanisms Linking Hyperglycemia-Induced Retinal Microvascular Injury to Diabetic Complications

Xizhi Zhang

doi:10.62177/amit.v2i5.1739

Authors

Xizhi Zhang Coppell High School

DOI:

https://doi.org/10.62177/amit.v2i5.1739

Keywords:

Diabetes Mellitus, Diabetic Retinopathy, Microvascular Injury, Diabetic Complications, Pathogenesis

Abstract

Background/Aim: Diabetic microvascular complications represent the leading causes of morbidity and mortality in patients with diabetes mellitus. Diabetic retinopathy (DR), as the most representative target-organ manifestation, demonstrates significant clinical comorbidity with systemic complications including nephropathy, neuropathy, foot disease, and cardiovascular events; however, the underlying integrative mechanisms remain inadequately systematized. This review aims to delineate the molecular and cellular mechanisms of hyperglycemia-induced retinal microvascular injury, explore the structural homology, shared pathways, and systemic bridge mediators linking this injury to major diabetic complications, and provide a theoretical basis for complication prevention and control from a "retina-systemic" network perspective. Methods: A systematic literature search was conducted across PubMed, Web of Science, Cochrane Library, and Embase for original research articles, systematic reviews, and meta-analyses published between 2010 and 2026. Search terms included "diabetic retinopathy," "microvascular injury," "diabetic complications," "hyperglycemia," "systemic inflammation," and "metabolic memory." A mechanistic integration analysis was performed on included studies. Results: Hyperglycemia induces retinal microvascular injury through activation of the polyol pathway, the advanced glycation end products (AGEs)-RAGE axis, protein kinase C (PKC)-β activation, oxidative stress, and NLRP3 inflammasome-mediated chronic inflammation, culminating in pericyte loss, blood-retinal barrier (BRB) disruption, and increased microvascular permeability. Retinal microvasculature exhibits high structural homology with glomerular, nerve endoneurial, and lower-extremity microvessels in basement membrane composition, pericyte coverage, and molecular pathways. Systemic low-grade inflammation, circulating endothelial progenitor cell (EPC) depletion, renin-angiotensin-aldosterone system (RAAS) activation, metabolic memory, epigenetic modifications, and gut microbiota dysbiosis serve as critical bridge mediators through which retinal injury mediates or predicts systemic multi-organ complications. Furthermore, retinal vascular parameters and DR staging demonstrate independent predictive value for systemic complication risk. Conclusions: Retinal microvascular injury is not merely an ocular complication of diabetes but constitutes an integral component of systemic microvascular disease and a "visual window" thereof. Early intervention targeting the shared molecular pathways and systemic mediators of hyperglycemia-induced microvascular injury holds significant clinical importance for the integrated prevention and management of diabetic multi-organ complications.

Downloads

Download data is not yet available.

References

International Diabetes Federation. (2021). IDF diabetes atlas (10th ed.). Brussels: IDF.

Antonetti, D. A., Klein, R., & Gardner, T. W. (2012). Diabetic retinopathy. The New England Journal of Medicine, 366(13), 1227–1239.

Yau, J. W., Rogers, S. L., Kawasaki, R., et al. (2012). Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 35(3), 556–564.

Cheung, N., Mitchell, P., & Wong, T. Y. (2010). Diabetic retinopathy. The Lancet, 376(9735), 124–136.

Cheung, N., & Wong, T. Y. (2008). Diabetic retinopathy and systemic complications. Progress in Retinal and Eye Research, 27(2), 161–176.

The Diabetes Control and Complications Trial Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine, 329(14), 977–986.

UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet, 352(9131), 837–853.

Giacco, F., & Brownlee, M. (2010). Oxidative stress and diabetic complications. Circulation Research, 107(9), 1058–1070.

Koya, D., Jirousek, M. R., Lin, Y. W., et al. (1997). Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. The Journal of Clinical Investigation, 100(1), 115–126.

Aiello, L. P., Avery, R. L., Arrigg, P. G., et al. (1994). Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. The New England Journal of Medicine, 331(22), 1480–1487.

Sheetz, M. J., & King, G. L. (2002). Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA, 288(20), 2579–2588.

Denton, R. M., Pullen, T. J., Armstrong, C. T., et al. (2020). The hexosamine biosynthetic pathway and O-GlcNAcylation. Biochemical Society Transactions, 48(4), 1563–1577.

Kowluru, R. A., & Chan, P. S. (2007). Oxidative stress and diabetic retinopathy. Experimental Diabetes Research, 2007, 43603.

Kowluru, R. A., & Abbas, S. N. (2003). Diabetes-induced mitochondrial dysfunction in the retina. Investigative Ophthalmology & Visual Science, 44(12), 5327–5334.

Zhong, Q., & Kowluru, R. A. (2011). Epigenetic modification of Sod2 in the development of diabetic retinopathy and in the metabolic memory: Role of histone methylation. Investigative Ophthalmology & Visual Science, 52(12), 9040–9048.

Zhou, R., Tardivel, A., Thorens, B., et al. (2010). Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nature Immunology, 11(2), 136–140.

Schroder, K., & Tschopp, J. (2010). The inflammasomes. Cell, 140(6), 821–832.

Tang, J., & Kern, T. S. (2011). Inflammation in diabetic retinopathy. Progress in Retinal and Eye Research, 30(5), 343–358.

Du, X. L., Edelstein, D., Dimmeler, S., et al. (2001). Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. The Journal of Clinical Investigation, 108(9), 1341–1348.

Antonetti, D. A., Barber, A. J., Hollinger, L. A., et al. (1999). Increased vascular permeability in the retina is linked to tight junction disassembly. Current Eye Research, 18(6), 435–441.

Armulik, A., Genove, G., Mae, M., et al. (2010). Pericytes regulate the blood-brain barrier. Nature, 468(7323), 557–561.

Hammes, H. P., Lin, J., Renner, O., et al. (2002). Pericytes and the pathogenesis of diabetic retinopathy. Diabetes, 51(10), 3107–3112.

Campochiaro, P. A. (2013). Ocular neovascularization. Journal of Molecular Medicine, 91(3), 311–321.

Tesfaye, S., Boulton, A. J., Dyck, P. J., et al. (2010). Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care, 33(10), 2285–2293.

Grunwald, J. E., Alexander, J., Maguire, M., et al. (2012). Retinopathy and chronic kidney disease in the Chronic Renal Insufficiency Cohort (CRIC) study. Archives of Ophthalmology, 130(9), 1136–1144.

Schalkwijk, C. G., & Stehouwer, C. D. A. (2020). Methylglyoxal, a highly reactive dicarbonyl compound, in diabetes, its vascular complications, and other age-related diseases. Physiological Reviews, 100(1), 407–461.

Aiello, L. P., Clermont, A., Arora, V., et al. (2006). Ruboxistaurin for diabetic macular edema: A randomized, double-masked, placebo-controlled, parallel, multicenter study. Ophthalmology, 113(11), 2021.e1–2021.e12.

Bierhaus, A., Humpert, P. M., Stern, D. M., et al. (2005). Understanding RAGE, the receptor for advanced glycation end products. Journal of Molecular Medicine, 83(11), 876–886.

Latz, E., Xiao, T. S., & Stutz, A. (2013). Activation and regulation of the inflammasomes. Nature Reviews Immunology, 13(6), 397–411.

Fadini, G. P., Coracina, A., Baesso, I., et al. (2006). Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. European Heart Journal, 27(18), 2247–2255.

Loomes, M. J., Al-Hussainy, S., Dodson, P. M., et al. (2023). Renin-angiotensin system blockade and retinopathy: A systematic review and meta-analysis. Eye, 37(1), 29–38.

Lewis, E. J., Hunsicker, L. G., Bain, R. P., et al. (1993). The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The New England Journal of Medicine, 329(20), 1456–1462.

Mauer, M., Zinman, B., Gardiner, R., et al. (2009). Renal and retinal effects of enalapril and losartan in type 1 diabetes. The New England Journal of Medicine, 361(1), 40–51.

El-Osta, A., Brasacchio, D., Yao, D., et al. (2008). Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. The Journal of Experimental Medicine, 205(10), 2409–2417.

Villeneuve, L. M., & Natarajan, R. (2010). The role of epigenetics in the pathology of diabetic complications. American Journal of Physiology-Renal Physiology, 299(1), F14–F25.

Brasacchio, D., Okabe, J., Tikellis, C., et al. (2009). Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes, 58(5), 1229–1236.

Ye, D., Ma, I., & Ma, T. Y. (2021). Intestinal microbiota: A new perspective in the pathogenesis and treatment of diabetic retinopathy. Frontiers in Cellular and Infection Microbiology, 11, 711833.

Zhang, Y., Zhang, S., Du, H., et al. (2023). Impaired gut microbiota and microbiota-derived metabolites in diabetic retinopathy. Diabetes Care, 46(4), e95–e96.

Wang, F. H., Liang, Y. B., Zhang, F., et al. (2012). The relationship between diabetic retinopathy and diabetic nephropathy in a Chinese type 2 diabetic population. Acta Diabetologica, 49(4), 289–295.

Cheung, N., Wang, J. J., Rogers, S. L., et al. (2008). Diabetic retinopathy and risk of heart failure. Journal of the American College of Cardiology, 51(16), 1573–1578.

Cheung, C. Y., Tikellis, G., Wang, J. J., et al. (2007). Quantitative retinal vascular caliber and risk of cardiovascular disease. The Lancet, 369(9576), 799–800.

Yau, J. W., Kawasaki, R., Islam, F. M., et al. (2010). Retinal fractal dimension and microvascular disease. Diabetes Care, 33(1), e14.

Spaide, R. F., Fujimoto, J. G., Waheed, N. K., et al. (2018). Optical coherence tomography angiography. Progress in Retinal and Eye Research, 64, 1–55.

de Carlo, T. E., Romano, A., Waheed, N. K., & Duker, J. S. (2015). A review of optical coherence tomography angiography (OCTA). International Journal of Retina and Vitreous, 1, 5.

White, N. H., Sun, W., Cleary, P. A., et al. (2008). Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology, 126(12), 1707–1715.

Zinman, B., Wanner, C., Lachin, J. M., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine, 373(22), 2117–2128.

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine, 375(4), 311–322.

Perkovic, V., Jardine, M. J., Neal, B., et al. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. The New England Journal of Medicine, 380(24), 2295–2306.

Heerspink, H. J. L., Stefansson, B. V., Correa-Rotter, R., et al. (2020). Dapagliflozin in patients with chronic kidney disease. The New England Journal of Medicine, 383(15), 1436–1446.

Ridker, P. M., Everett, B. M., Thuren, T., et al. (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. The New England Journal of Medicine, 377(12), 1119–1131.

Coll, R. C., Robertson, A. A., Chae, J. J., et al. (2015). A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine, 21(3), 248–255.

Murphy, M. P., & Smith, R. A. J. (2007). Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annual Review of Pharmacology and Toxicology, 47, 629–656.